Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4006668 | 1.00 | TSHR (0.56) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL4968131 | 0.91 | TSHR (0.61) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL13762659 | 0.83 | TSHR (0.56) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL9165420 | 0.83 | DGKA (0.36) | TSHRLMNAALDH1A1MAPT | |
| SCHEMBL13762658 | 0.83 | TSHR (0.56) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL10119664 | 0.83 | TSHR (0.56) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL1968935 | 0.82 | TSHR (0.57) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL3502791 | 0.82 | TSHR (0.82) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL1286873 | 0.82 | TSHR (0.82) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL118000 | 0.82 | TSHR (0.82) | TSHRLMNAALDH1A1CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572398-B2 | GLP-1 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2023-02-07 | — | — | US | disclosed |
| CN-106999602-B | GLP-1 derivatives and uses thereof | 诺和诺德股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-105722526-B | Selective PYY compounds and uses thereof | 诺和诺德股份有限公司 | 2020-12-08 | — | — | CN | disclosed |
| EP-3033112-B1 | GLP-1 DERIVATIVES, AND USES THEREOF | NOVO NORDISK AS (DK) | 2020-10-07 | — | — | EP | disclosed |
| EP-3673921-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | Baxalta GmbH (CH) | 2020-07-01 | — | — | EP | disclosed |
| EP-2654794-B1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | Baxalta GmbH (CH) | 2020-03-04 | — | — | EP | disclosed |
| EP-3226906-B1 | GLP-1 DERIVATIVES AND USES THEREOF | NOVO NORDISK AS (DK) | 2019-06-12 | — | — | EP | disclosed |
| US-10266577-B2 | GLP-1 derivatives, and uses thereof | NOVO NORDISK A/S (DK) | 2019-04-23 | — | — | US | disclosed |
| EP-3068421-B1 | SELECTIVE PYY COMPOUNDS AND USES THEREOF | NOVO NORDISK AS (DK) | 2019-04-17 | — | — | EP | disclosed |
| US-10246497-B2 | Selective PYY compounds and uses thereof | NOVO NORDISK A/S (DK) | 2019-04-02 | — | — | US | disclosed |
| CN-105451776-A | GLP-1 derivatives and uses thereof | NOVO NORDISK AS | 2016-03-30 | — | — | CN | disclosed |
| US-9085637-B2 | Selective PYY compounds and uses thereof | NOVO NORDISK A/S (DK) | 2015-07-21 | — | — | US | disclosed |
| US-20150152150-A1 | Selective PYY compounds and uses thereof | NOVO NORDISK A/S (DK) | 2015-06-04 | — | — | US | disclosed |
| WO-2015071355-A1 | SELECTIVE PYY COMPOUNDS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015022400-A1 | GLP-1 DERIVATIVES, AND USES THEREOF | NOVO NORDISK A/S (DK) | 2015-02-19 | — | — | WO | disclosed |
| US-8945897-B2 | Materials and methods for conjugating a water soluble fatty acid derivative to a protein | BAXTER INTERNATIONAL INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2654794-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | Baxter International Inc (US) | 2013-10-30 | — | — | EP | disclosed |
| CN-103269723-A | Materials and methods for conjugating a water soluble fatty acid derivative to a protein | BAXTER INT | 2013-08-28 | — | — | CN | disclosed |
| US-20120190096-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | BAXTER HEALTHCARE S.A. (CH) | 2012-07-26 | — | — | US | disclosed |
| WO-2012087838-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | BAXTER INTERNATIONAL INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266577-B2 | GLP-1 derivatives, and uses thereof | GLP1R, IAPP, GCG | TSHR 639/4885LMNA 1793/4885ALDH1A1 1949/4885 |
| US-20120190096-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | FABP1, FABP4, FABP5 | TSHR 3304/4885LMNA 2670/4885ALDH1A1 2674/4885 |
| US-20150152150-A1 | Selective PYY compounds and uses thereof | NPY1R, NPY5R, NPY2R | TSHR 417/4885LMNA 4017/4885ALDH1A1 4809/4885 |
| US-11572398-B2 | GLP-1 derivatives and uses thereof | GLP1R, GIPR, GCG | TSHR 642/4885LMNA 537/4885ALDH1A1 2013/4885 |
| US-10246497-B2 | Selective PYY compounds and uses thereof | NPY1R, NPY5R, NPY2R | TSHR 417/4885LMNA 4017/4885ALDH1A1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.